Linking Projects to Strategy at Medtech Custom Case Solution & Analysis

1. Evidence Brief

Financial Metrics

• Project Volume: Medtech currently carries 75 active projects across three business units.
• Budget Allocation: R&D spending is 12% of annual revenue, yet only 15% of projects launched in the last three years met their original ROI targets.
• Resource Over-commitment: Engineering staff are allocated to an average of 4.2 projects simultaneously; internal data suggests a 30% productivity loss due to context switching.
• Revenue Concentration: 80% of current year growth is derived from 5 legacy product extensions, while breakthrough projects have seen a 24-month average delay.

Operational Facts

• Capacity Gap: Total estimated man-hours required for the current portfolio exceed actual engineering capacity by 165%.
• Project Categorization: Projects are nominally classified as Derivative, Platform, or Breakthrough, but 60% of Breakthrough projects are actually mislabeled incremental improvements.
• Geographic Footprint: R&D is split between the US and Germany, with no centralized tracking system for cross-border resource sharing.
• Cycle Time: Average time-to-market has increased from 18 months to 31 months over the last five years.

Stakeholder Positions

• The CEO: Demands a 25% revenue contribution from new products but continues to approve pet projects outside the formal review process.
• Business Unit (BU) Managers: Compete for shared resources; prioritize short-term derivative projects to hit quarterly bonuses.
• R&D Director: Reports total burnout among lead engineers; advocates for a moratorium on new project starts.
• Finance Committee: Uses a scoring model based on Net Present Value (NPV) that fails to account for strategic fit or technical risk.

Information Gaps

• Kill-Rate Data: The case does not specify the historical percentage of projects terminated before launch.
• Specific Competitor Benchmarks: Detailed R&D cycle times for Medtech’s primary rivals are absent.
• Skill Inventory: There is no data on whether the current engineering talent possesses the specific competencies required for the Breakthrough projects in the pipeline.

2. Strategic Analysis

Core Strategic Question

• How can Medtech rationalize a bloated R&D portfolio to align resource allocation with long-term strategic growth while eliminating the 165% capacity-demand mismatch?

Structural Analysis

Application of the Aggregate Project Plan (APP) framework reveals a fundamental imbalance in Medtech’s innovation engine. The portfolio is heavily weighted toward low-risk, low-reward derivative projects that consume 70% of resources but provide only incremental differentiation. The bargaining power of BU managers allows for project proliferation, undermining the CEO’s breakthrough objectives. The current NPV-heavy scoring model creates a bias toward certain short-term gains, effectively starving long-term strategic initiatives of the necessary talent.

Strategic Options

Preliminary Recommendation

Medtech must adopt Strategic Bucketing combined with an immediate Portfolio Pruning exercise. The current 165% over-allocation is a mathematical impossibility that guarantees failure across all projects. By ring-fencing resources for Breakthrough and Platform projects, Medtech protects its future growth from being cannibalized by minor product tweaks.

3. Implementation Roadmap

Critical Path

• Month 1: Portfolio Audit and Suspension. Freeze all new project starts. Audit the existing 75 projects against two metrics: Strategic Alignment and Resource Intensity.
• Month 2: The Cut. Terminate all projects scoring in the bottom quartile of strategic alignment. Consolidate remaining projects until total man-hour requirements equal 95% of actual capacity.
• Month 3: Governance Redesign. Establish a cross-functional Portfolio Management Office (PMO) with the authority to reallocate resources across BUs.
• Month 4: Launch Strategic Buckets. Re-assign lead engineers to ring-fenced Breakthrough teams with 100% dedication to single projects.

Key Constraints

• BU Autonomy: Business Unit managers will likely hide project work or use shadow R&D resources to maintain their local priorities.
• Data Integrity: Current time-tracking is unreliable; the PMO will initially struggle to measure true resource consumption.

Risk-Adjusted Implementation Strategy

To mitigate cultural resistance, the CEO must tie BU Manager incentives to the success of the entire portfolio, not just their specific unit. A 10% capacity buffer must be maintained to handle the inevitable technical hurdles in Breakthrough projects. If productivity does not increase by Month 6, a second round of pruning will be triggered automatically.

4. Executive Review and BLUF

BLUF

Medtech is failing because it treats R&D as an infinite resource. The current portfolio is 65% over capacity, ensuring that even the most promising projects will miss market windows. Leadership must immediately terminate 30 projects to restore operational sanity. Strategy is defined by what the company stops doing. Without a hard pivot to strategic bucketing and centralized resource governance, Medtech will remain a legacy manufacturer of incremental improvements while competitors capture the breakthrough market. Immediate action is required to prevent a total collapse of R&D productivity.

Dangerous Assumption

The most dangerous assumption is that the current engineering staff is fungible. The plan assumes that engineers freed from derivative projects can immediately contribute to breakthrough medical technology without significant retraining or new hiring. This overlooks a potential specialized skill gap.

Unaddressed Risks

• Talent Attrition: High-performing engineers may exit the organization during the disruptive transition from BU-centric to centralized R&D governance. Probability: High. Consequence: Severe.
• Market Timing: Aggressive pruning of derivative projects may leave a 12-month revenue gap before new platform products reach commercialization. Probability: Medium. Consequence: Moderate.

Unconsidered Alternative

Medtech could pursue an Open Innovation/M&A Model. Rather than attempting to fix an internal R&D culture that is structurally biased toward derivatives, the company could shift its focus to acquiring startups that have already cleared the breakthrough technical hurdles, using its existing sales force to scale those products. This bypasses the internal resource allocation conflict entirely.

VERDICT: APPROVED FOR LEADERSHIP REVIEW